PPI-668 + BI 207127 + faldaprevir + ribavirin

This combination is an **investigational oral regimen for the treatment of chronic hepatitis C virus (HCV) infection**, composed of four antiviral agents: - **PPI-668**: a potent, pan-genotypic HCV NS5A inhibitor developed by Presidio Pharmaceuticals. - **BI 207127 (deleobuvir)**: a non-nucleoside inhibitor of the HCV polymerase (NS5B), developed by Boehringer Ingelheim, active mainly against genotype 1. - **Faldaprevir (BI 201335)**: an oral, once-daily HCV NS3/4A protease inhibitor from Boehringer Ingelheim. - **Ribavirin**: a broad-spectrum antiviral nucleoside analog, usually combined with other anti-HCV agents. The regimen was studied in Phase 2 trials as a potential **interferon-free, all-oral therapy** for HCV genotype 1 infection, with and without ribavirin, aiming to achieve rapid and sustained virologic responses (SVR) with improved tolerability. Boehringer Ingelheim and Presidio Pharmaceuticals collaborated in these clinical trials focused on patients with genotype 1a HCV infection[1][3][5].